The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: A systematic review
Panagiotis Filis1, Ioannis Zerdes2, Theodora Soumala3
1Department of Oncology/Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.
Background:
The advent of targeted therapies signaled novel avenues for more optimal oncological outcomes. Antibody-drug conjugates (ADCs) have risen as a cornerstone of the ever-expanding targeted therapy era. The purpose of this systematic review is to delineate the rapidly evolving clinical landscape of ADCs for solid tumors.
Methods:
A literature search was performed in Medline, Embase and Cochrane databases for phase II and III clinical trials. Outcomes of interest were the objective response rate, overall survival, progression-free survival and adverse events.
Results:
A total of 92 clinical trials (76 phase II and 16 phase III) evaluated the efficacy and safety of ADCs for a plethora of solid tumors. Out of the 30 investigated ADCs, 8 have received approval by regulatory organizations for solid tumors. Currently, 52 phase III clinical trials for ADCs are ongoing.
Conclusion:
ADCs have shown promising results for several solid tumors and various cancer settings.
Insights
Antibody-drug conjugates (ADCs) show promise in treating solid tumors. This review summarizes their evolving clinical landscape, efficacy, and safety, highlighting ongoing research and approved therapies.
Area of Science:
- Oncology
- Pharmacology
Background:
- Antibody-drug conjugates (ADCs) represent a significant advancement in targeted cancer therapy.
- This systematic review focuses on the clinical application of ADCs in solid tumors.
Approach:
- Systematic literature search of phase II and III clinical trials in Medline, Embase, and Cochrane databases.
- Evaluation of objective response rate, overall survival, progression-free survival, and adverse events.
Key Points:
- 92 trials (76 phase II, 16 phase III) assessed ADC efficacy and safety in various solid tumors.
- 8 out of 30 investigated ADCs are approved for solid tumors.
- 52 phase III trials for ADCs are currently underway.
Conclusions:
- ADCs demonstrate promising efficacy and safety profiles across diverse solid tumor types and treatment settings.
- The field of ADCs for solid tumors is rapidly evolving with substantial ongoing clinical investigation.
